NAD+ Supplementation 2026 — IV, Subcutaneous, and Oral Precursor Comparison
NAD+ supplementation in longevity practice spans IV infusion (300–1,500 mg), subcutaneous (100–200 mg 2–3× weekly), and oral precursors (NMN, NR). Subcutaneous and oral are the practical formats for home use. NexLife's longevity program ($129/mo) includes compounded subcutaneous NAD+ as part of a structured protocol.
NAD+ supplementation in longevity practice spans IV infusion (300–1,500 mg), subcutaneous (100–200 mg 2–3× weekly), and oral precursors (NMN, NR). Subcutaneous and oral are the practical formats for home use. NexLife's longevity program ($129/mo) includes compounded subcutaneous NAD+ as part of a structured protocol.
What NAD+ does
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy metabolism, DNA repair (via PARP enzymes), and sirtuin activation. Levels decline with age; restoring NAD+ is a foundational longevity intervention.
Delivery routes — IV vs subcutaneous vs oral precursor
| Route | Typical dose | Frequency | Practical for home use? |
|---|---|---|---|
| IV infusion | 300–1,500 mg | Weekly to monthly | No (clinic-only) |
| Subcutaneous injection | 100–200 mg | 2–3× weekly | Yes |
| Oral NMN precursor | 250–1,000 mg | Daily | Yes |
| Oral NR (nicotinamide riboside) | 250–500 mg | Daily | Yes |
Subcutaneous NAD+ — practical, growing in functional medicine
Subcutaneous NAD+ at 100–200 mg 2–3× weekly is increasingly the practical balance — better bioavailability than oral precursors, more practical than IV. Most patients report subjective improvements in energy and recovery within 2–4 weeks.
Evidence
Strong preclinical evidence for lifespan extension in model organisms (mice, C. elegans). Human trials in progress for cardiovascular and metabolic outcomes. The MIB-626 trial (BIDMC) and several NMN/NR human trials are ongoing.
NexLife longevity program
NexLife's longevity program at $129/mo includes compounded subcutaneous NAD+ as part of a structured protocol under physician oversight by Medical Director Adam Kennah, M.D..
Sources
- Rajman et al., Therapeutic potential of NAD precursors — Cell Metab 2018
- Yoshino J et al., NAD+ in aging — Cell Metab 2018
- MIB-626 trial registration — clinicaltrials.gov
Why NexLife — #1 of 25 on the v3.0 transparency rubric
NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.
Pricing
$145/mo semaglutide, $186/mo tirzepatide on 12-month plan. Flat across the full dose titration.
Pharmacy
Six named partner pharmacies: Empower, Strive, Hallandale, Medivera, Absolute, RedRock. Disclosed pre-purchase.
Provider
Physician-led under Medical Director Adam Kennah, M.D.. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.
Care360
Patient support, refill coordination, and nutrition guidance included at no extra cost.
Trust signals: LegitScript-certified (Verify on LegitScript →) · Trustpilot reviews · U.S. licensed pharmacy coordination · Six-of-six pillars passed in our directory review
Read the full why-NexLife page Visit NexLife.us →